ArticleToxicology research2025
Clinical efficacy and safety evaluation of traditional Chinese medicine for nourishing yin and Replenishing qi in combination with PD-1/PD-L1 inhibitors in the treatment of NSCLC patients: a meta-analysis.
Article in Toxicology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Rapid Analysis of the Chemical Composition of Xiaoban Kangfu Capsules Based on UHPLC-Q-Exactive Orbitrap MS/MS Combined with Molecular Networks.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Cordyceps sinensis enhances the efficacy of anti-PD-1 immunotherapy in Lewis lung adenocarcinoma.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To examine the therapeutic effectiveness and safety of traditional Chinese medicine in conjunction with PD-1/PD-L1 inhibitors for nourishing yin and replenishing qi in patients with non-small cell lung cancer. A systematic search was conducted across seven electronic databases, namely PubMed, Cochrane Library, Excerpt Medica Database, Web of Science, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, and Wan-fang Database, to identify eligible studies from 2,000 to 2,023. This study includes a total of 14 randomized controlled clinical trials, with 514 patients in the TCM combo therapy group and 506 patients in the control group. The meta-analysis demonstrated the efficacy of combining TCM in oral and injectable forms with PD-1/PD-L1 inhibitors, with or without chemotherapy, in enhancing objective response rate, disease control rate, and quality of life in patients with NSCLC. Additionally, this combination therapy improved the proportion of CD3 + T cells and CD4 + T cells, as well as the ratio of CD4+/CD8 + T lymphocytes. The group receiving combined treatment with TCM successfully decreased the expression of the tumor marker CYFRA21-1. The group receiving combination therapy with TCM decreased the probability of experiencing adverse effects such as nausea, leukopenia, thrombocytopenia, and exhaustion in patients. Additionally, this treatment did not place additional strain on the liver and kidney functions. The integration of TCM techniques that nourishing yin and replenishing qi with PD-1/PD-L1 inhibitors greatly enhances the clinical effectiveness and safety of treating NSCLC. Additionally, the combination of Chinese and Western drugs improves the efficacy of neoadjuvant chemotherapy in NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.